ĐÁNH GIÁ TÁC DỤNG CỦA VIÊN NANG GK1 ĐIỀU TRỊ SUY THẬN MẠN TRÊN LÂM SÀNG

Abstract

Objectives: To evaluate the efficacy of GK1 capsules in treating chronic kidney disease without clinical indications for renal replacement therapy. Subjects and methods: 60 patients with stage I, II, and IIIa chronic kidney disease were divided into two groups: the GK1 group (n=30, taking 6 capsules of GK1 per day) and the control group (n=30, taking 10 tablets of Ketosteril per day). The study duration was 30 days. This was a prospective, controlled study, comparing pre- and post-treatment outcomes. Results: After 30 days, the GK1 group exhibited a glomerular filtration rate (44.86 ± 8.96 ml/minute/1.73m²) higher than that before treatment (41.23 ± 7.76 ml/minute/1.73m²), and higher than the control group (36.93 ± 11.16 ml/minute/1.73m²), p < 0.05. General treatment efficacy: The proportion of patients showing effectiveness in the GK1 group (40%) was higher compared to the control group (6.67%), (p < 0.05). Additionally, the GK1 group improving common traditional Chinese medicine symptoms such as back pain, nocturia, leg cramps… especially in CKD patients with phlegm dampness and damp-heat. During the study period, there were no adverse effects observed with GK1 capsules. Conclusions: GK1 capsules are safe and effective in increasing glomerular filtration rate and improving common symptoms in patients with chronic kidney disease without clinical indications for renal replacement therapy, especially in those with phlegm dampness and damp-heat.